Nihon Kohden has expanded its portfolio of neurology electrode devices by acquiring a 71.4% stake in NeuroAdvanced Corp., the parent company of Ad-Tech Medical Instrument Corporation.
The Japanese company noted that acquisition 鈥淣ihon Kohden鈥檚 established expertise in electro encephalograph (EEG) systems with Ad-Tech鈥檚 specialized electrodes, strengthening the company鈥檚 ability to support comprehensive epilepsy care.鈥�
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Archimed, an investment firm and previous owner of Ad-Tech, has the remaining stake in Ad-Tech and will act as a minority joint venture partner with Nihon Kohden. The acquisition is estimated to cost approximately 楼16bn ($103.66m).
GlobalData estimates that the is expected to expand from being worth approximately $13.1bn in 2024 to over $20.8bn by 2033. The neurological diagnostic and monitoring equipment device segment is expected to grow from $1.5bn to over $1.7bn over the same period.
Nihon Kohden noted that the acquisition is part of the company鈥檚 long-term BEACON 2030 vision. As part of FY2023 H1 financial statement, the company stated that as part of Phase II of BEACON 2030 vision it plans to make research and development (R&D) investments in patient monitors, ventilators, and Digital Health Solutions. The R&D investments total approximately 楼23.5bn ($152m).
鈥淭his acquisition represents a pivotal step in advancing critical solutions for epilepsy care,鈥� said Roy Sakai, President of Nihon Kohden America. 鈥淏y uniting our strengths, we鈥檙e enhancing our ability to provide end-to-end support for epilepsy鈥攆rom accurate diagnosis to advanced interventions.鈥�
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAdding that this collaboration helps support these solutions for patients in acute neurocritical care situations, preserving function and enabling precision with intraoperative neuromonitoring (IONM) and enhancing usefulness of patient data using its analytics and digital health solutions (DHS).
Nihon Kohden鈥檚 portfolio consists of diagnostics systems such as EEG, electrocardiograph (ECG), automated haematology analysers, patient monitors, and treatment equipment including defibrillator, and pacemakers.
